All stock lists
Royalty Pharma plc (NASDAQ:RPRX)
US · Delayed Price · Currency is USD
Healthcare · Medical - Pharmaceuticals
64.83+0.97 (+1.52%)
Insider Score
––Not scored
RPRX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
RPRX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 674.14 M | 630.58 M | 621.99 M | 609.29 M | 578.66 M | 568.25 M |
| Revenue Growth (YoY) | 16.50 % | 10.97 % | 4.78 % | 7.90 % | 7.71 % | 0.05 % |
| Cost of Revenue | 268.22 M | 1.17 M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 405.93 M | 629.40 M | 621.99 M | 609.29 M | 578.66 M | 568.25 M |
| SG&A Expense | 161.89 M | 159.00 M | 164.27 M | 118.73 M | 179.77 M | 110.70 M |
| R&D Expense | 97.85 M | 40.00 M | 51.00 M | 50.50 M | 300.50 M | 50.50 M |
| Operating Expenses | 272.81 M | -3.08 M | 233.61 M | 182.13 M | 368.87 M | 34.06 M |
| Operating Income | 133.00 M | 632.48 M | 388.38 M | 427.16 M | 209.80 M | 534.18 M |
| Pretax Income | 81.49 M | 468.26 M | 355.91 M | 444.21 M | 90.64 M | 433.43 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 17.88 M | 295.00 M | 214.21 M | 288.22 M | 30.18 M | 238.35 M |
| EPS (Basic) | 0.04 | 0.68 | 0.64 | 1.05 | 0.09 | 0.55 |
| EPS (Diluted) | 0.04 | 0.53 | 0.50 | 0.67 | 0.07 | 0.41 |
| Shares Outstanding | 445.06 M | 431.89 M | 431.89 M | 431.89 M | 423.51 M | 435.48 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.